// App-Quantinova.ai

3052 : A Randomized Comparison Of Maintenance Therapy With Subcutaneous Rituximab For 2 Years Versus Until Progression In Patients With Indolent Non-Hodgkins Lymphoma: Interim Safety Data From The Mabcute Study

Researchers

Presenter

  • Simon Rule

Principal Investigators

  • Javier Briones

  • Angelo Michele Carella

  • Olivier Casasnovas

  • Wolney Gois Barreto

  • Christopher Pocock

  • Stuart Osborne

  • Rodney Smith

  • Francesco Zaja

Medical Centers

  • Haematology Clinic, CHU Le Bocage, Dijon, France

  • Department of Haematology, Santa Marcelina Hospital, Sao Paulo, Brazil

  • Department of Haematology, Derriford Hospital, Plymouth, United Kingdom

  • East Kent Hospitals, Canterbury, United Kingdom

  • Haematology Clinic, AOUD S. M. Misericordia, Udine, Italy

  • IRCCS San Martino - IST, Genoa, Italy

  • Department of Hematology, Santa Creu i Sant Pau Hospital, Barcelona, Spain

Locations

  • Brazil

  • Italy

  • Spain

  • United Kingdom

  • France

Companies

  • Feng Chi Biotech Cor

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

Disease

  • Mucosa-associated lymphoid tissue lymphoma

  • Non-Hodgkin's Lymphoma

  • Hodgkin's Lymphoma

  • Pulmonary embolism

  • Familial non-Hodgkin lymphoma

  • Neutropenia

  • Viral myocarditis

  • Non‐Hodgkin Lymphoma

  • Venous thrombosis

  • Lymphomas

  • Sepsis

Biomarkers

  • B-lymphocyte antigen CD20

  • DNA Damage Inducible Transcript 3

Drug/Treatment

  • Rituximab

  • Bendamustine

  • Carbetimer

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved